{
  "id": "cddd88f60f50b40a",
  "title": "STAT+: Eczema drug from Nektar Therapeutics maintains skin responses in one-year study",
  "description": "An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding investor expectations.",
  "content": "An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding investor expectations.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/02/10/nektar-therapeutics-rezpeg-eczema-drug-maintains-skin-response-study/?utm_campaign=rss",
  "published_at": "2026-02-10T12:00:00+00:00",
  "fetched_at": "2026-02-11T00:34:18.892628+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug",
    "ai"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Eczema drug from Nektar Therapeutics maintains skin responses in one-year study",
    "description": "An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding investor expectations.",
    "url": "https://www.statnews.com/2026/02/10/nektar-therapeutics-rezpeg-eczema-drug-maintains-skin-response-study/?utm_campaign=rss",
    "published": "2026-02-10T12:00:00+00:00",
    "source": "STAT"
  }
}